The international Journal of Drug Delivery Science and Technologywill publish the scientific article in the August edition titled "Cold isostatic pressing of hydrating calcium sulfate as a means to produce parenteral slow-release formulations".
The NanoZolid® technology has, over the course of several years, demonstrated its ability to enable a controlled release of a wide range of drugs following a single parenteral injection, resulting in stable and pharmacologically relevant plasma exposure levels over the desired time period. LIDDS has a number of active projects for the intratumoral treatment of cancer and also for the use of NanoZolid® technology as a subcutaneous depot to achieve sustained and controlled systemic drug release.
"The article describes the fundamentals and versatility of the NanoZolid® technology and will strengthen the international recognition of NanoZolid®, a patented and innovative technology platform suitable for many different types of drugs and for both intratumoral and subcutaneous administration," says Monica Wallter, CEO of LIDDS. NanoZolid® formulations for intratumoral drug delivery enables a high drug load and efficacy in cancer tumors combined with small risks for systemic adverse effects resulting in increased quality of life for cancer patients.
NanoZolid® formulated drugs for subcutaneous systemic release can overcome issues with frequent treatments and low compliance, giving patients and healthcare providers new and innovative treatment options. There is a significant need for this type of technology in a wide range of disease areas, for example in psychiatric, endocrine and inflammatory diseases.
LIDDS collaborates with Karolinska Institutet for the research and development of new NanoZolid®-based drug formulations.
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: monica.wallter@liddspharma.com
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical phase for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North. For more information, please visit liddspharma.com.
—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LIDDS AB via Globenewswire